


Novel End-to-end Platform for Scalable and Efficient Manufacturing of Extracellular Vesicles EVscale[™] - Extracellular Vesicles at scale

Phoenestra GmbH February 2024

The Case for Extracellular Vesicles



Extracellular Vesicles (EV) are **natural and universal 'cargo ships'** between cells in all organisms and tissues



Li M, Fang F, Sun M, Zhang Y, Hu M, Zhang J. Extracellular vesicles as bioactive nanotherapeutics: An emerging paradigm for regenerative medicine. Theranostics. 2022 Jun 21;12(11):4879-4903. doi: 10.7150/thno.72812. PMID:35836815; PMCID: PMC9274746.


Broad Therapeutic potential in Regenerative Medicine

Conditions linked to overshooting or chronic inflammatory conditions and fibrosis

- Acute Lung Inflammation
- Lung Fibrosis
- Liver Fibrosis
- Heart fibrosis
- Kidney Fibrosis
- Brain and Peripheral Nerve Injury
- CNS Inflammation and Neurodegeneration

Market Potential for EV-based Therapies





Update Nov 2023:

2022 ... USD 12.2 billion (actuals) 2027 ... USD 40.6 billion (projected, CAGR 27.2%)

Regenerative Medicine Market Size, Share, Trends and Revenue Forecast [Latest] (marketsandmarkets.com)


EV market size 2022-2032 Trend Analysis Report

2022: USD 0.25 billion 2032: USD 3.2 billion (CAGR 29.7%) Thereof ca. 50% diagnostics (Driver: Cancer) USD 150 million in 2022 for therapeutics Ca. 55% of Global Market in US

It is expected that EV-based therapeutics may capture a very significant portion of the projected Regenerative Medicine Market

Exosomes Market Size & Share – Trends Analysis Report, 2032 (gminsights.com)

Current Main Issues for EV-based Therapeutics





Phoenestra Provides Solutions for Current Issues -Introducing EVs*cale*™



Topics	Value Proposition of EVscale™
Stable Cell Lines (MSC/TERT*)	 Consistent growth profile Tiered Cell Banking Concept (Master Cell Bank (MCB)/Working Cell Bank (WCB) instead of donor variability Fully documented (GMP-ready)
Scalable and Consistent Manufacturing	 Continuous manufacturing for high productivity Consistent EV composition and quality Scalable and easy to transfer into the GMP environment GMP manufacturing services (from 2024)
Bioassays / Potency*	 Many relevant biological functionalities are covered Link to (pre-)clinical translation
Extended Characterization*/**	 Linking RNA profiles and protein, lipid composition to biological functionalities Composition-function relationships
Biomarker Development **	Supportive tools and data for product development and clinical development
~~~	2

With EVscale[™], Phoenestra provides a leading end-to-end approach for cellderived EV product candidates which opens ample opportunities for a 'pipeline from a Technology Platform'

- Batch-to-batch consistency
- Scalability
- Leading Cost of Manufacturing



**in collaboration with TAMRNA Busi

Business Use only © Phoenestra GmbH

## EVscale[™] from Different Telomerized MSC Lines End-to-end Approach



#### Cryovial

MSC/TERT from different human tissues (see below) Fully documented and characterized Tiered cell banking possible GMP-ready

Seed train

#### Bioreactor-based expansion**


Fully controlled bioreactorbased cultivation Consistent EV quality Tunable biological functionalities Productive and scalable Fast translation into GMP

#### Downstream processing

Gentle membrane methods (TFF) Chromatographic separation Scalable and GMPready unit operations


#### EV characterization

Standard methods NanoFCM RNA sequencing Potency assays Composition-function relationships





© Nalgene Thermo Fisher Scientific and Phoenestra GmbH

MSC/TERT lines licensed from Evercyte GmbH EV characterization in collaboration with Evercyte and TAmiRNA GmbH









## The Proprietary EVscale[™] Cultivation Platform






#### **Main Design Features**

- Simple, scalable
- Sanitary, easy to clean
- Bioreactor brand agnostic
- Adherent cells are within a well perfused basket system
- May be used with a wide range of cell carriers

# Key Performance Data for MSC/TERT in a 250 mL DASbox bioreactor unit (Eppendorf AG)

- High specific surface area
- High cell densities even for difficult-to-grow cells, such as MSC/TERT from different tissues
- High volumetric productivity feasible




phoenestra

Business Use only © Phoenestra GmbH

## Phoenestra is the Best Partner for Your EV Project



- Broad range of fully characterized and documented MSC lines from different donors/tissues
  - Bone Marrow, Adipose tissue, Wharton's Jelly, Placenta, Chorionic Plate, Reflected Amnion, Endometrial or
  - Custom-made
- Scalable platform process for straight forward process development
- Different Downstream processing options available
- In-depth analytical characterization methods are well established
- Including functional bioassays for process and product analysis and definition
- GMP cell banking and processing (from Q4 2024)
- Experienced project management single face to the customer



phoenestra



## Get in touch and let's talk about your needs!

Klaus Graumann, CEO and co-founder Phoenestra GmbH klaus.graumann@phoenestra.com

Otto Kanzler, CFO and co-founder Phoenestra GmbH otto.kanzler@phoenestra.com

www.phoenestra.com

Business Use only © Phoenestra GmbH